Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo

Virology

Volumn 429, Issue 1, 2012, Pages 12-20

  Williams, Katherine L ^a   Wahala, Wahala M P B ^b   Orozco, Susana ^a   De Silva, Aravinda M ^b   Harris, Eva ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dengue; Enhancement; Envelope domain III; Mouse model; Protection

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DENGUE VIRUS 2; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIREMIA; VIRUS ENVELOPE DOMAIN III; VIRUS LOAD; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; DENGUE; DENGUE VIRUS; FEMALE; HUMANS; MALE; MICE; MICE, 129 STRAIN; PROTEIN STRUCTURE, TERTIARY; SPECIES SPECIFICITY; VIRAL ENVELOPE PROTEINS;

DENGUE VIRUS; MUS;

EID: 84861183266     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.03.003     Document Type: Article

References (53)

1. Alvarez D., Vollmann E.H., von Andrian U.H. Mechanisms and consequences of dendritic cell migration. Immunity 2008, 29(3):325-342.
2. Balsitis S.J., Williams K.L., Lachica R., Flores D., Kyle J.L., Mehlhop E., Johnson S., Diamond M.S., Beatty P.R., Harris E. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010, 6(2):e1000790.
3. Beltramello M., Williams K.L., Simmons C.P., Macagno A., Simonelli L., Quyen N.T., Sukupolvi-Petty S., Navarro-Sanchez E., Young P.R., de Silva A.M., Rey F.A., Varani L., Whitehead S.S., Diamond M.S., Harris E., Lanzavecchia A., Sallusto F. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010, 8(3):271-283.
4. Block O.K., Rodrigo W.W., Quinn M., Jin X., Rose R.C., Schlesinger J.J. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 2010, 28(51):8085-8094.
5. Burke D.S., Monath T.P. Flaviviruses. Fields Virology 2001, 1. Lippincott Williams and Wilkins, Philadelphia. 4th ed. D.M. Knipe, P.M. Howley (Eds.).
6. Chau T.N., Hieu N.T., Anders K.L., Wolbers M., Lien L.B., Hieu L.T., Hien T.T., Hung N.T., Farrar J., Whitehead S., Simmons C.P. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of vietnamese infants. J. Infect. Dis. 2009, 200(12):1893-1900.
7. Cockburn J.J., Navarro Sanchez M.E., Goncalvez A.P., Zaitseva E., Stura E.A., Kikuti C.M., Duquerroy S., Dussart P., Chernomordik L.V., Lai C.J., Rey F.A. Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. Embo. J. 2011.
8. Crill W.D., Chang G.J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 2004, 78(24):13975-13986.
9. Crill W.D., Hughes H.R., Delorey M.J., Chang G.J. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 2009, 4(4):e4991.
10. Crill W.D., Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 2001, 75(16):7769-7773.
11. de Alwis R., Beltramello M., Messer W.B., Sukupolvi-Petty S., Wahala W.M., Kraus A., Olivarez N.P., Pham Q., Brian J., Tsai W.Y., Wang W.K., Halstead S., Kliks S., Diamond M.S., Baric R., Lanzavecchia A., Sallusto F., de Silva A.M. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis. 2011, 5(6):e1188.
12. Dejnirattisai W., Jumnainsong A., Onsirisakul N., Fitton P., Vasanawathana S., Limpitikul W., Puttikhunt C., Edwards C., Duangchinda T., Supasa S., Chawansuntati K., Malasit P., Mongkolsapaya J., Screaton G. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328(5979):745-748.
13. Effler P.V., Pang L., Kitsutani P., Vorndam V., Nakata M., Ayers T., Elm J., Tom T., Reiter P., Rigau-Perez J.G., Hayes J.M., Mills K., Napier M., Clark G.G., Gubler D.J. Dengue fever, Hawaii, 2001-2002. Emerg. Infect. Dis. 2005, 11(5):742-749.
14. Endy T.P., Nisalak A., Chunsuttitwat S., Vaughn D.W., Green S., Ennis F.A., Rothman A.L., Libraty D.H. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 2004, 189(6):990-1000.
15. Gromowski G.D., Barrett A.D. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 2007, 366(2):349-360.
16. Gromowski G.D., Barrett N.D., Barrett A.D. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 2008, 82(17):8828-8837.
17. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 2003, 60:421-467.
18. Halstead S.B. Dengue. Lancet 2007, 370(9599):1644-1652.
19. Innis B.L. Antibody responses to dengue virus infection. Dengue and Dengue Hemorrhaggic Fever 1997, 221-243. CAB Int., New York. D.J. Gubler, G. Kuno (Eds.).
20. Kliks S.C., Nimmanitya S., Nisalak A., Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 1988, 38(2):411-419.
21. Kreil T.R., Maier E., Fraiss S., Eibl M.M. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J. Virol. 1998, 72(4):3076-3081.
22. Kyle J.L., Balsitis S., Zhang L., Beatty P.R., Harris E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 2008, 380:296-303.
23. Lai C.Y., Tsai W.Y., Lin S.R., Kao C.L., Hu H.P., King C.C., Wu H.C., Chang G.J., Wang W.K. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 2008, 82(13):6631-6643.
24. Libraty D.H., Acosta L.P., Tallo V., Segubre-Mercado E., Bautista A., Potts J.A., Jarman R.G., Yoon I.K., Gibbons R.V., Brion J.D., Capeding R.Z. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 2009, 6(10):e1000171.
25. Lin B., Parrish C.R., Murray J.M., Wright P.J. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 1994, 202(2):885-890.
26. Lok S.M., Kostyuchenko V., Nybakken G.E., Holdaway H.A., Battisti A.J., Sukupolvi-Petty S., Sedlak D., Fremont D.H., Chipman P.R., Roehrig J.T., Diamond M.S., Kuhn R.J., Rossmann M.G. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 2008, 15(3):312-317.
27. Midgley C.M., Bajwa-Joseph M., Vasanawathana S., Limpitikul W., Wills B., Flanagan A., Waiyaiya E., Tran H.B., Cowper A.E., Chotiyarnwon P., Grimes J.M., Yoksan S., Malasit P., Simmons C.P., Mongkolsapaya J., Screaton G.R. An in-depth analysis of original antigenic sin in dengue virus infection. J. Virol. 2010, 85(1):410-421.
28. Modis Y., Ogata S., Clements D., Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 2003, 100(12):6986-6991.
29. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8(1):34-47.
30. Oliphant T., Nybakken G.E., Austin S.K., Xu Q., Bramson J., Loeb M., Throsby M., Fremont D.H., Pierson T.C., Diamond M.S. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 2007, 81(21):11828-11839.
31. Oliphant T., Nybakken G.E., Engle M., Xu Q., Nelson C.A., Sukupolvi-Petty S., Marri A., Lachmi B.E., Olshevsky U., Fremont D.H., Pierson T.C., Diamond M.S. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 2006, 80(24):12149-12159.
32. Ravetch J.V., Anderson C.L. FcγR family: proteins, transcripts and genes. Fc Receptors and the Action of Antibodies 1990, 211-235. American Society for Microbiology, Washington, DC. H. Metzger (Ed.).
33. Rey F.A., Heinz F.X., Mandl C., Kunz C., Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995, 375(6529):291-298.
34. Rodhain F., Rosen L. Mosquito vectors and dengue virus-vector relationships. Dengue and Dengue Hemorrhagic Fever 1997, 45-60. CAB Int., New York. D.J. Gubler, G. Kuno (Eds.).
35. Roehrig J.T., Bolin R.A., Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246(2):317-328.
36. Rothman A.L. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr. Top. Microbiol. Immunol. 2010, 338:83-98.
37. Sabin A.B. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1952, 1(1):30-50.
38. Schieffelin J.S., Costin J.M., Nicholson C.O., Orgeron N.M., Fontaine K.A., Isern S., Michael S.F., Robinson J.E. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol. J. 2010, 7:28.
39. Shresta S., Kyle J.L., Snider H.M., Basavapatna M., Beatty P.R., Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J. Virol. 2004, 78(6):2701-2710.
40. Shresta S., Sharar K.L., Prigozhin D.M., Beatty P.R., Harris E. A murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 2006, 80:10208-10217.
41. Shrestha B., Brien J.D., Sukupolvi-Petty S., Austin S.K., Edeling M.A., Kim T., O'Brien K.M., Nelson C.A., Johnson S., Fremont D.H., Diamond M.S. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010, 6(4):e1000823.
42. Sukupolvi-Petty S., Austin S.K., Engle M., Brien J.D., Dowd K.A., Williams K.L., Johnson S., Rico-Hesse R., Harris E., Pierson T.C., Fremont D.H., Diamond M.S. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 2010, 84(18):9227-9239.
43. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., Roehrig J.T., Gromowski G.D., Barrett A.D., Fremont D.H., Diamond M.S. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 2007, 81(23):12816-12826.
44. Trirawatanapong T., Chandran B., Putnak R., Padmanabhan R. Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 1992, 116(2):139-150.
45. Valdes I., Bernardo L., Gil L., Pavon A., Lazo L., Lopez C., Romero Y., Menendez I., Falcon V., Betancourt L., Martin J., Chinea G., Silva R., Guzman M.G., Guillen G., Hermida L. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009, 394(2):249-258.
46. Valdes I., Gil L., Romero Y., Castro J., Puente P., Lazo L., Marcos E., Guzman M.G., Guillen G., Hermida L. The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin. Vaccine Immunol. 2011, 18(3):455-459.
47. van den Broek M.F., Muller U., Huang S., Aguet M., Zinkernagel R.M. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 1995, 69(8):4792-4796.
48. von Andrian U.H., Mempel T.R. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 2003, 3(11):867-878.
49. Wahala W.M., Donaldson E.F., de Alwis R., Accavitti-Loper M.A., Baric R.S., de Silva A.M. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 2010, 6(3):e1000821.
50. Wahala W.M., Kraus A.A., Haymore L.B., Accavitti-Loper M.A., de Silva A.M. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009, 392(1):103-113.
51. WHO Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention, and Control 1997, WHO.
52. Williams K.L., Zompi S., Beatty P.R., Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann. N Y Acad. Sci. 2009, 1171(Suppl 1):E12-E23.
53. Xie H., Li X., Gao J., Lin Z., Jing X., Plant E., Zoueva O., Eichelberger M.C., Ye Z. Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice. Clin. Infect. Dis. 2011, 53(12):1179-1187.